Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin and Gut Flora in Diarrhea-Predominant IBS
ChiCTR-OPC-15007624Phase 4Recruiting
- Sponsor
- Union Hospital of Huazhong University of Science and Technology
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of rifaximin in Diarrhea-predominant irritable bowel syndrome (IBS-D) (5 arms), sponsored by Union Hospital of Huazhong University of Science and Technology. Primary endpoint: gut flora. Started Jan 2016; status: recruiting.
02
Drugs
rifaximin
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on ChiCTR-OPC-15007624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-15007624.